Sanofi is ditching the mRNA Covid-19 vaccine after rivals’ success

Sanofi is ditching the mRNA Covid-19 vaccine after rivals' success

September 29, 2021: -On Tuesday, Sanofi is dropping plans for its mRNA-based Covid-19 vaccine because of the dominance achieved by BioNTech-Pfizer, and Moderna uses the technology to fight the pandemic, the company said.

The move highlights the challenges of competing with pioneer BioNTech, which rose from obscurity through its alliance with pharma major Pfizer in the previous year. They have delivered close to 1.5 billion doses to become the Western world’s largest Covid-19 vaccine maker.

French healthcare group Sanofi will focus on efforts with British partner GlaxoSmithKline to bring another Covid-19 vaccine candidate to market based on the conventional protein-based approach, where mass trials are ongoing.

On Tuesday, the decision to drop clinical development of a shot based on mRNA, or messenger RNA, acquired as part of its takeover of Translate Bio, came despite positive Phase I/II study interim results announced where participants’ blood readings showed a robust immune reaction.

Sanofi said the read-out encouraged it only to pursue the technology as a potential vaccine against influenza and other diseases, which gives up on the area of Covid-19 because of the strong market presence of the two approved mRNA shots.

“The results are significant as they show us that the platform we acquired works,” Thomas Triomphe, head of the Sanofi Pasteur vaccines division, told journalists. He kicks off final Phase III trials now made no sense.

“Would it be the best use of this wealth of science afforded by mRNA vaccines to make a Covid-19 vaccine and try and bring one more mRNA Covid-19 vaccine to people who already today may not want an mRNA Covid-19 vaccine? Clearly not,” Triomphe said.

He added that by May or June 2022, 24 billion doses of Covid-19 jabs made by different manufacturers would have been delivered, which adds to the disincentives to produce a vaccine candidate when Covid-19 was unlikely to require vaccination based annually, instead of the flu.

Sanofi’s shares were flat at 82.1 euros by 1026 GMT, outperforming a 1.37% not approved in the STOXX Europe 600 Health Care.

“The decision of RNA looks to be interpreted as positive since they will save development costs and concentrate on the different products and ventures,” said Ion-Marc Valahu, a fund manager at Geneva from investment firm Clairinvest.

About Us

We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.

Recent Posts

CalFoods Logistics | Making A Difference for those in Need | Steve Linkhart

Steve Linkhart, CEO of CalFoods Logistics, believes that he possesses one quality that sets the tone for CalFoods Logistics. “When we hire a new team member, there are clear responsibilities that need to be accomplished. Once we hire, train, and let that person take the ownership of the job, we allow them to do their job,” he explains. “We are always there to assist of course, but I feel that people get a sense of ownership of their role when they are allowed to do so. Everyone has a role from being CEO to pulling or entering orders, everyone has their unique responsibilities, and the foundation is always customer service, without that, everything after is on shaky ground.” Steve feels that there isn’t a role here too big or too small for anyone to jump in and help. He has unloaded his fair share of trucks and pulled orders over the past 18 months and will be glad to do it again if needed. “Taking care of our team is of the utmost importance to me. We offer a living wage, amazing benefits, and time off for the team to have a good work/life balance.”

Innovana Solutions | Leading with Determination & Commitment | Mitch McDermid

When Mitch McDermid launched Innovana, he had an evident vision of what he wanted the company to look like and what it could offer that was different from existing IT services and consulting firms. There was a clear need for a cloud-based services and business automation solutions provider that would address the needs of SMBs both from a pricing and service standpoint in Canada. Mitch and his team have been laser-focused on serving that niche.

Arete Wealth | Offering Excellence & Virtue | Joshua D. Rogers

A forward thinker, Joshua D. Rogers is always focused on the future. His vision was to introduce a smart, sophisticated approach to investing and wealth building. Since founding Arete Wealth in 2007, he’s done just that. Joshua’s brought an endowment-style of asset allocation to a broader audience of investors. From hedge funds to bespoke investments, his dream was to bring a new perspective to investing. Arete Wealth is the embodiment of that vision: a dynamic, energetic, comprehensive wealth management firm focused on the future.

OnView Integrated Solutions | The Guardian Angel | Joel Anaya

Joel Anaya, CEO of OnView Integrated Solutions, has been instrumental in building the company from the ground up. His innovation and vision transformed the way the company has scaled its business. OnView is a security provider bringing proactive solutions specifically designed to deter suspicious behavior in real-time before the crime occurs.